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ABSTRACT 
Objective: To develop a simple and a cheap UV spectrophotometric assay method for the estimation of Eplerenone in tablets and validate as per 
ICH guidelines.  
Methods: The optimized method uses 100% potassium dihydrogen orthophosphate, pH 2.0 as a solvent for the estimation of assay of Eplerenone in 
tablets at a detection wavelength of 245 nm.  
Results: The developed method resulted in Eplerenone exhibiting linearity in the range 5-15μg/ml. System precision and intra-day precision are 
exemplified by relative standard deviation of 1.17% and 0.94% respectively. Method was found to be rugged as precision was found to be 1.52%. 
Percentage Mean recovery was found to be in the range of 98-102 by percentage method during accuracy studies.  
Conclusion: A simple and a cheap UV spectrophotometric assay method were developed and validated for the estimation of Eplerenone in tablets 
as per ICH guidelines and hence it can be used for routine analysis in various pharmaceutical industries.  
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Eplerenone (fig. 1) is pregen-4-ene-7,21-dicarboxylic acid, 9,11-
epoxy-17-hydroxy-3-oxo,γ-lactone, methyl ester (7α,11α,17α)[1,3]. 
It has a molecular formula of C
INTRODUCTION 
24H30O6 and a molecular mass of 
414.49. Eplerenone is the first highly selective aldosterone receptor 
antagonist (SARA) to effectively block aldosterone at receptor sites 
in body tissues, aldosterone being a component of rennin-
angiotensin-aldosterone system [1-6]. Eplerenone is used for 
treatment of hypertension and heart failure [1-6]. Eplerenone is 
specifically indicated for the reduction of risk of cardiovascular 
death in people with heart failure and left ventricular dysfunction 
within 3–14 d of an acute myocardial infarction, in combination with 
standard therapies and as treatment against hypertension. It 
appears equivalent to spironolactone but is much more 
expensive [7]. It is marketed by Pfizer under the trade name Inspra. 
Eplerenone is a potassium-sparing diuretic, meaning that it helps the 
body get rid of water but still keep potassium. Few analytical 
methods have been reported for the determination of Eplerenone in 
biological fluids by LCMS [8-9], in bulk and formulations by UV 
spectroscopy [10-11], TLC/Densitometry [1] and RP-HPLC [3, 12]. 
UV assay methods were reported [10-11] using methanol (30%) and 
methanol (70%) in water as solvent respectively. Both the UV 
methods are costlier due to use of organic solvent methanol. Hence, 
we here report a simple and a cheap UV spectrometric assay method 
for the estimation of Eplerenone in tablets using aqueous solution of 
potassium dihydrogen orthophosphate buffer (pH 2.0).  
 
 
Fig. 1: Structure of Eplerenone 
MATERIALS AND METHODS 
Materials 
Instrument 
A double beam UV-visible spectrophotometer (Shimadzu, model 
1800) having two matched quartz cells with 1 cm light path and 
loaded with UV probe software (version 2.41) was used for 
recording of spectra and measuring absorbance. An electronic 
analytical weighing balance (0.1 mg sensitivity, Shimadzu AY 220), 
digital pH meter (DELUX model 101) and a sonicator (sonica, model 
2200 MH) were used in this study.  
Chemicals and reagents 
Analytically pure sample of Eplerenone with purities greater than 
99% was obtained as gift sample from Chandra labs, Hyderabad, 
India and tablet formulation [PLANEP] was procured from Medplus 
pharmacy, Hyderabad, India with labelled claim of 25 mg. Potassium 
dihydrogen orthophosphate (AR Grade), Ortho phosphoric acid were 
obtained from SD Fine chemicals (Hyderabad, India).  
Method 
Preparation of buffer as solvent 
1.36 g of potassium dihydrogen ortho phosphate was added to 500 
ml of distilled water to get a clear solution whose pH was adjusted to 
2.0 with ortho phosphoric acid. 
Selection of suitable detection wavelength 
Suitable wavelength for the total experiment was determined by 
recording UV spectrum in the range of 200-400 nm for Eplerenone 
and suitable wavelength selected was 245 nm (fig. 2). 
Preparation of stock and working standard solution 
10 mg of Eplerenone was accurately weighed and taken in 100 ml 
clean and dry volumetric flask containing 80 ml of solvent and then the 
solution was made up to the mark using the solvent. This is considered 
as standard stock solution (100µg/ml). 1 ml of the stock solution was 
pipetted out and made up to 10 ml to get a concentration 10µg/ml, 
treated as the working standard, 100% target concentration.  
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Preparation of stock and working sample solution 
Not less than 20 tablets were taken and converted in to powder 
using pestle and mortar. Test stock solution of 500μg/ml was 
prepared by transferring weight equivalent to 25 mg of Eplerenone 
to 40 ml of solvent which is sonicated and shaken intermittently for 
15 min and later made up to 50 ml with solvent. This solution was 
filtered using 0.22micron syringe filter. From the above stock 
solution 0.2 ml was pipetted out and made up to 10 ml to get 
working sample solution concentration equivalent to 10µg/ml, 
100% target concentration. 
 
Fig. 2: UV spectrum of standard 
 
RESULTS AND DISCUSSION 
Method development 
Various solvents were explored including water, potassium 
dihydrogen orthophosphate solution at various pH’s, Hydrochloric 
acid at 0.1N and 0.05N and sodium hydroxide at 0.1N and 0.05N. 
Eplerenone was found to be soluble and stable for minimum of 1 hour 
at room temperature using potassium dihydrogen ortho phosphate 
solution at pH 2.0 and hence this solvent was initiated for the 
determination of suitable detection wavelength and working standard. 
In order to test the applicability of the developed method to a 
commercial formulation, assay of PLANEP tablets were studied at 
working concentration. Assay for working concentration of sample at 
245 nm was in acceptance limits (95-105%) using the solvent via 
intermittent shaking and sonication method for 15 min fig. 3 illustrates 
UV spectrum for the sample. Hence the method is optimized.  
Method validation 
Validation of the analytical method is the process that establishes by 
laboratory studies in which the performance characteristics of the 
method meet the requirements for the intended analytical 
application. UV spectrophotometric method developed was 
validated according to International Conference on Harmonization 
(ICH) guidelines [13] for validation of analytical procedures. The 
method was validated for the parameters like linearity, accuracy, 




Six replicate recording of absorbance at 245 nm of standard solution 
at working concentration showed % RSD (Relative Standard 
Deviation) less than 2, which indicates acceptable reproducibility 
and thereby the precision of the system. System precision results are 
tabulated in table 1. 
Method precision 
Method precision was determined by performing assay of sample 
under the tests of (i) repeatability (Intraday precision) and (ii) 
Intermediate precision (Inter day precision or ruggedness) 
performed during 2 consecutive days by two different analysts, at 
working concentration.  
 
 
Fig. 3: UV spectrum of sample 
 












Repeatability (Intraday precision) 
Six consecutive recording of absorbance at 245 nm of the sample 
from the same homogeneous mixture at working concentration 
showed % RSD less than 2 concerning % assay, which indicate that 
the method developed is method precise by the test of repeatability 
and hence can be understood that the method gives consistently 
reproducible results (table 2).  
 
Table 2: Intraday precision results of eplerenone 
n Sample absorbance % Assay 
1  0.427  99 
2 0.429 99.46 
3 0.429 99.46 
4 0.433 101.40 
5 0.435 100.85 
6 0.432 100.15 
Average  100.05 
SD  0.94 
% RSD  0.94 
 
Intermediate precision (Inter day precision/Ruggedness) 
Assay precision between two consecutive days performed by 
different analysts of the sample showed % RSD less than 2, which 
indicate the method developed is inter day precise/rugged (table 3). 
Linearity 
Standard solutions of Eplerenone at different concentrations level 
(50%, 75%, 100%, 125% and 150%) were prepared. Calibration 
curve (fig. 4) was constructed by plotting the concentration level of 
drug versus absorbance at 245 nm. The results show an excellent 
correlation between absorbance and concentration level of drug 
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within the concentration range (5-15µg/ml) for the drug (table 4). 
The correlation coefficient was greater than 0.995, which meet the 
method validation acceptance criteria and hence the method is said 
to be linear in the range of 5-15µg/ml. 
 
Table 3: Inter day precision results 
n Analyst 1 Analyst 2 
1 99 98.05 
2 99.46 96.91 
3 99.46 97.37 
4 101.46 100.85 
5 100.85 99.31 
6 100.15 99.69 
Average 100.05 98.69 
SD 0.94 1.5 
%RSD 0.94 1.52 
 
Table 4: Calibration data for Eplerenone 
% Level Concentration (µg/ml) Absorbance 
50 5 0.244 
75 7.5 0.318 
100 10 0.399 
125 12.5 0.467 
150 15 0.544 
Regression equation: y=0.299x+0.0948, Regression coefficient: 0.999 
Accuracy 
Accuracy was determined by means of recovery experiments, by the 
determination of % mean recovery of sample by percentage method 
at three different levels (50-150%). At each level, three 
determinations were performed. Percent mean recovery was 
calculated as shown in table 5. The accepted limits of recovery are 
98%-102% and all observed data are within the required range 
which indicates good recovery values and hence the accuracy of the 
method developed. Table 6 summarizes the validation parameters. 
 
 
Fig. 4: Linearity graph of Eplereone 
 











50 0.225 100.22   
50 0.228 101.26 100.7 0.225 
50 0.224 100.88   
100 0.436 97.99   
100 0.441 100.3 99.09 0.439 
100 0.441 98.98   
150 0.647 96.98   
150 0.653 98.07 98.44 0.655 
150 0.667 100.28   
 
Table 6: Optical characteristics and validation parameters of Eplerenone 
Parameters Results 
Detection wavelength (nm) 245 
Beer’s Law limits (µg/ml) 5-15 
Regression equation (y = mx+c) y=0.299x+0.0948 
Correlation coefficient (r2 0.999 ) 
Slope (m) 0.299 
Intercept (c) 0.0948 
% Relative Standard Deviation (% RSD) System precision 1.17 
(% RSD) Intra-day precision 0.94 
(% RSD) Inter-day precision ≤ 2 
Accuracy (% Mean Recovery)  
 50 % Level 100.7 
 100 % Level 99.09 
 150 % Level 98.44 
 
CONCLUSION 
A simple UV spectrophotometric method was developed and validated 
for the quantitative estimation of Eplerenone in capsules as per ICH 
guidelines. The optimized method uses 100% potassium dihydrogen 
orthophosphate, pH 2.0 as a solvent for the estimation of assay of 
Eplerenone in tablets at a detection wavelength of 245 nm. The 
developed method resulted in Eplerenone exhibiting linearity in the 
range 5-15μg/ml.  
System precision and intra-day precision are exemplified by relative 
standard deviation of 1.17% and 0.94% respectively. Method was 
found to be rugged as precision was found to be 1.52%. Percentage 
Mean recovery was found to be in the range of 98-102 by percentage 
method during accuracy studies. Accordingly it is concluded that the 
developed UV spectrophotometric assay method is simple, accurate, 
precise, linear and rugged and therefore the method can be used for 
the routine analysis of Eplerenone in tablets in various pharmaceutical 
industries. 
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